SAB Biotherapeutics’ (SABS) “Buy” Rating Reaffirmed at Chardan Capital

SAB Biotherapeutics (NASDAQ:SABS)‘s stock had its “buy” rating reissued by stock analysts at Chardan Capital in a research report issued on Wednesday,Benzinga reports. They presently have a $25.00 price target on the stock.

Several other analysts also recently commented on the stock. Craig Hallum assumed coverage on shares of SAB Biotherapeutics in a research report on Wednesday, October 9th. They issued a “buy” rating and a $11.00 target price for the company. HC Wainwright reiterated a “buy” rating and issued a $6.00 price objective on shares of SAB Biotherapeutics in a report on Wednesday. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, SAB Biotherapeutics currently has an average rating of “Buy” and an average target price of $12.40.

SAB Biotherapeutics Stock Performance

SABS opened at $2.17 on Wednesday. The stock has a fifty day moving average price of $3.61 and a 200 day moving average price of $3.12. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.69 and a quick ratio of 3.69. SAB Biotherapeutics has a 1 year low of $2.00 and a 1 year high of $6.30.

SAB Biotherapeutics (NASDAQ:SABS) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.07) by ($0.05). SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.37%. As a group, equities analysts expect that SAB Biotherapeutics will post -3.69 EPS for the current year.

Institutional Trading of SAB Biotherapeutics

An institutional investor recently raised its position in SAB Biotherapeutics stock. HB Wealth Management LLC boosted its position in shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) by 118.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 237,400 shares of the company’s stock after acquiring an additional 128,800 shares during the period. HB Wealth Management LLC owned 2.57% of SAB Biotherapeutics worth $982,000 at the end of the most recent quarter. Institutional investors and hedge funds own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.